Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Identifieur interne : 000240 ( Ncbi/Curation ); précédent : 000239; suivant : 000241Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Auteurs : Christelle Gouhier [France] ; Sylvie Chalon ; Anne Aubert-Pouessel ; Marie-Claire Venier-Julienne ; Christophe Jollivet ; Jean-Pierre Benoit ; Denis GuilloteauSource :
- Synapse (New York, N.Y.) [ 0887-4476 ] ; 2002.
English descriptors
- KwdEn :
- Animals, Corpus Striatum (drug effects), Corpus Striatum (metabolism), Disease Models, Animal, Dopamine (metabolism), Dopamine Plasma Membrane Transport Proteins, Glial Cell Line-Derived Neurotrophic Factor, Male, Membrane Glycoproteins, Membrane Transport Proteins (metabolism), Microspheres, Nerve Growth Factors, Nerve Tissue Proteins (administration & dosage), Neurons, Afferent (drug effects), Neurons, Afferent (metabolism), Neuroprotective Agents (administration & dosage), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Rats, Rats, Wistar, Substantia Nigra (drug effects), Substantia Nigra (metabolism).
- MESH :
- chemical , administration & dosage : Nerve Tissue Proteins, Neuroprotective Agents.
- chemical , metabolism : Dopamine, Membrane Transport Proteins.
- drug effects : Corpus Striatum, Neurons, Afferent, Substantia Nigra.
- drug therapy : Parkinson Disease.
- metabolism : Corpus Striatum, Neurons, Afferent, Parkinson Disease, Substantia Nigra.
- Animals, Disease Models, Animal, Dopamine Plasma Membrane Transport Proteins, Glial Cell Line-Derived Neurotrophic Factor, Male, Membrane Glycoproteins, Microspheres, Nerve Growth Factors, Rats, Rats, Wistar.
Abstract
The use of glial cell line-derived neurotrophic factor (GDNF) appears to be a promising strategy to promote survival and function of the nigrostriatal dopaminergic pathway damaged in Parkinson's disease (PD). However, effective intracerebral administration is required for optimal therapeutic benefit and tools to evaluate such therapies must be developed. A rodent model of PD was therefore developed using striatal injection of 6-hydroxydopamine (6-OHDA) with simultaneous implantation of GDNF-delivering microspheres. The effects of GDNF released from microspheres were assessed by classical methods such as amphetamine-induced rotating behavior and tyrosine hydroxylase (TH) immunoreactivity, as well as by quantitative autoradiography using PE2I, a dopamine transporter (DAT) radiotracer, which is also suitable for SPET imaging in humans. 6-OHDA-lesioned animals that received microspheres without GDNF were used as controls. During the first 3 weeks after simultaneous lesion and implantation, the amphetamine-induced rotating behavior of GDNF-treated rats was improved compared to controls and an increase in TH expression (+26%) was measured in the striatum 6 weeks after lesion. In accordance with these results, an increase in striatal PE2I-labeled DAT density was obtained (+17%) after 3 and 6 weeks of treatment. In conclusion, this study demonstrates the neuroprotective action of GDNF delivered by microspheres and suggests that PE2I may be an appropriate radiotracer for use in SPET scintigraphy to follow up treatment of PD in humans.
DOI: 10.1002/syn.10063
PubMed: 11954043
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001189
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001148
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001148
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000240
Links to Exploration step
pubmed:11954043Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.</title><author><name sortKey="Gouhier, Christelle" sort="Gouhier, Christelle" uniqKey="Gouhier C" first="Christelle" last="Gouhier">Christelle Gouhier</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U316, Laboratoire de Biophysique Médicale et Pharmaceutique, Université François Rabelais, UFR des Sciences Pharmaceutiques, 37200 Tours, France. gouhier@univ-tours.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U316, Laboratoire de Biophysique Médicale et Pharmaceutique, Université François Rabelais, UFR des Sciences Pharmaceutiques, 37200 Tours</wicri:regionArea><placeName><region type="region" nuts="2">Centre-Val de Loire</region><region type="old region" nuts="2">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation></author><author><name sortKey="Chalon, Sylvie" sort="Chalon, Sylvie" uniqKey="Chalon S" first="Sylvie" last="Chalon">Sylvie Chalon</name></author><author><name sortKey="Aubert Pouessel, Anne" sort="Aubert Pouessel, Anne" uniqKey="Aubert Pouessel A" first="Anne" last="Aubert-Pouessel">Anne Aubert-Pouessel</name></author><author><name sortKey="Venier Julienne, Marie Claire" sort="Venier Julienne, Marie Claire" uniqKey="Venier Julienne M" first="Marie-Claire" last="Venier-Julienne">Marie-Claire Venier-Julienne</name></author><author><name sortKey="Jollivet, Christophe" sort="Jollivet, Christophe" uniqKey="Jollivet C" first="Christophe" last="Jollivet">Christophe Jollivet</name></author><author><name sortKey="Benoit, Jean Pierre" sort="Benoit, Jean Pierre" uniqKey="Benoit J" first="Jean-Pierre" last="Benoit">Jean-Pierre Benoit</name></author><author><name sortKey="Guilloteau, Denis" sort="Guilloteau, Denis" uniqKey="Guilloteau D" first="Denis" last="Guilloteau">Denis Guilloteau</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:11954043</idno><idno type="pmid">11954043</idno><idno type="doi">10.1002/syn.10063</idno><idno type="wicri:Area/PubMed/Corpus">001189</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001189</idno><idno type="wicri:Area/PubMed/Curation">001148</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001148</idno><idno type="wicri:Area/PubMed/Checkpoint">001148</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001148</idno><idno type="wicri:Area/Ncbi/Merge">000240</idno><idno type="wicri:Area/Ncbi/Curation">000240</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.</title><author><name sortKey="Gouhier, Christelle" sort="Gouhier, Christelle" uniqKey="Gouhier C" first="Christelle" last="Gouhier">Christelle Gouhier</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U316, Laboratoire de Biophysique Médicale et Pharmaceutique, Université François Rabelais, UFR des Sciences Pharmaceutiques, 37200 Tours, France. gouhier@univ-tours.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U316, Laboratoire de Biophysique Médicale et Pharmaceutique, Université François Rabelais, UFR des Sciences Pharmaceutiques, 37200 Tours</wicri:regionArea><placeName><region type="region" nuts="2">Centre-Val de Loire</region><region type="old region" nuts="2">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation></author><author><name sortKey="Chalon, Sylvie" sort="Chalon, Sylvie" uniqKey="Chalon S" first="Sylvie" last="Chalon">Sylvie Chalon</name></author><author><name sortKey="Aubert Pouessel, Anne" sort="Aubert Pouessel, Anne" uniqKey="Aubert Pouessel A" first="Anne" last="Aubert-Pouessel">Anne Aubert-Pouessel</name></author><author><name sortKey="Venier Julienne, Marie Claire" sort="Venier Julienne, Marie Claire" uniqKey="Venier Julienne M" first="Marie-Claire" last="Venier-Julienne">Marie-Claire Venier-Julienne</name></author><author><name sortKey="Jollivet, Christophe" sort="Jollivet, Christophe" uniqKey="Jollivet C" first="Christophe" last="Jollivet">Christophe Jollivet</name></author><author><name sortKey="Benoit, Jean Pierre" sort="Benoit, Jean Pierre" uniqKey="Benoit J" first="Jean-Pierre" last="Benoit">Jean-Pierre Benoit</name></author><author><name sortKey="Guilloteau, Denis" sort="Guilloteau, Denis" uniqKey="Guilloteau D" first="Denis" last="Guilloteau">Denis Guilloteau</name></author></analytic><series><title level="j">Synapse (New York, N.Y.)</title><idno type="ISSN">0887-4476</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Glial Cell Line-Derived Neurotrophic Factor</term><term>Male</term><term>Membrane Glycoproteins</term><term>Membrane Transport Proteins (metabolism)</term><term>Microspheres</term><term>Nerve Growth Factors</term><term>Nerve Tissue Proteins (administration & dosage)</term><term>Neurons, Afferent (drug effects)</term><term>Neurons, Afferent (metabolism)</term><term>Neuroprotective Agents (administration & dosage)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Rats</term><term>Rats, Wistar</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Nerve Tissue Proteins</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term><term>Membrane Transport Proteins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Neurons, Afferent</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Neurons, Afferent</term><term>Parkinson Disease</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Glial Cell Line-Derived Neurotrophic Factor</term><term>Male</term><term>Membrane Glycoproteins</term><term>Microspheres</term><term>Nerve Growth Factors</term><term>Rats</term><term>Rats, Wistar</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The use of glial cell line-derived neurotrophic factor (GDNF) appears to be a promising strategy to promote survival and function of the nigrostriatal dopaminergic pathway damaged in Parkinson's disease (PD). However, effective intracerebral administration is required for optimal therapeutic benefit and tools to evaluate such therapies must be developed. A rodent model of PD was therefore developed using striatal injection of 6-hydroxydopamine (6-OHDA) with simultaneous implantation of GDNF-delivering microspheres. The effects of GDNF released from microspheres were assessed by classical methods such as amphetamine-induced rotating behavior and tyrosine hydroxylase (TH) immunoreactivity, as well as by quantitative autoradiography using PE2I, a dopamine transporter (DAT) radiotracer, which is also suitable for SPET imaging in humans. 6-OHDA-lesioned animals that received microspheres without GDNF were used as controls. During the first 3 weeks after simultaneous lesion and implantation, the amphetamine-induced rotating behavior of GDNF-treated rats was improved compared to controls and an increase in TH expression (+26%) was measured in the striatum 6 weeks after lesion. In accordance with these results, an increase in striatal PE2I-labeled DAT density was obtained (+17%) after 3 and 6 weeks of treatment. In conclusion, this study demonstrates the neuroprotective action of GDNF delivered by microspheres and suggests that PE2I may be an appropriate radiotracer for use in SPET scintigraphy to follow up treatment of PD in humans.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000240 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000240 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:11954043
|texte= Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:11954043" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |